Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.45 |
| ▸ | MPO | P05164 | 5/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6346399 | 1.00 | TAAR1 (0.48) | TAAR1HSPA5MPOMGLLCYP2D6 | |
| SCHEMBL6342128 | 1.00 | TAAR1 (0.48) | TAAR1HSPA5MPOMGLLCYP2D6 | |
| SCHEMBL3571928 | 0.88 | TAAR1 (0.56) | TAAR1HSPA5MPOCYP2D6TSHR | |
| SCHEMBL8142434 | 0.82 | TAAR1 (0.50) | TAAR1HSPA5MPOMGLLCYP2D6 | |
| SCHEMBL13976392 | 0.81 | TAAR1 (0.58) | TAAR1HSPA5MPOCYP2D6TSHR | |
| SCHEMBL3879663 | 0.81 | SLC6A2 (0.55) | TAAR1HIF1ASLC6A4IDO1 | |
| SCHEMBL4930328 | 0.81 | TAAR1 (0.48) | TAAR1HSPA5MPOMGLLCYP2D6 | |
| SCHEMBL4930332 | 0.81 | TAAR1 (0.48) | TAAR1HSPA5MPOMGLLCYP2D6 | |
| SCHEMBL14271048 | 0.81 | HTR1A (0.49) | TAAR1HSPA5MPOMGLLCYP2D6 | |
| SCHEMBL9308109 | 0.81 | HTR1A (0.49) | TAAR1HSPA5MPOMGLLCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014818-A1 | Process for producing optically active chroman derivative and intermediate | KANEKA CORPORATION (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1445324-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMAN DERIVATIVE AND INTERMEDIATE | KANEKA CORPORATION (JP) | 2004-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014818-A1 | Process for producing optically active chroman derivative and intermediate | CYP8B1, CYP3A43, HPD | TAAR1 4465/4885HSPA5 1623/4885MPO 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.